Ultragenyx Pharmaceutical Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ultragenyx Pharmaceutical (Novato, CA): 2 reconciled FDA prescription therapies, $39.0M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterNovato, CA
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2034-01-01
2024 CMS Total Public Spend$39.0M
2024 Medicare Part D Spend$5.6M
2024 Medicaid Spend$33.5M
California HCAI SB 17 Filings2 WAC filings (max 19.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Ultragenyx Pharmaceutical across sibling Meru public-data platforms.